Lupin Launches Generic Vfend® Tablets and Vfend® Oral Suspension in the US


Mumbai, Baltimore, December 19, 2016: Pharma Major Lupin Limited (Lupin) announced today that it has launched its Voriconazole Tablets, 50 mg & 200 mg and Voriconazole Oral Suspension, 40 mg/mL having received an approval from the United States Food and Drug Administration (FDA) earlier to market a generic equivalent of PF Prism C.V’s Vfend® Tablets, 50 mg & 200 mg and Vfend® Oral Suspension, 40 mg/mL.

Voriconazole Tablets, 50 mg & 200 mg and Voriconazole Oral Suspension, 40 mg/mL are the AB rated generic equivalent of PF Prism C.V’s Vfend® Tablets, 50 mg & 200 mg and Vfend® Oral Suspension, 40 mg/mL. It is indicated for use in patients 12 years of age and older in the treatment of the following fungal infections:

  • Invasive Aspergillosis
  • Candidemia in Non-neutropenic patients and the following Candida infections: Disseminated infections in skin and infections in abdomen, kidney, bladder wall and wounds
  • Esophageal Candidiasis
  • Serious fungal infections caused by Scedosporium apiospermum (Asexual form of Pseudallescheria boydii) and Fusarium spp. including Fusarium solani in patients intolerant of or refractory to other therapy

Vfend® Tablets, 50mg & 200mg had US sales of USD 81 million (IMS MAT September 2016) while Vfend® Oral Suspension, 40 mg/mL had US sales of USD 15.2 million (IMS MAT September 2016).

About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 6th and the 8th largest generics pharmaceutical company by market capitalization and sales globally (September 30th, 2016, Bloomberg). The Company is the 5th largest pharmaceutical player in the US by prescriptions (4.68% market share – IMS Health, National Prescription Audit, March 2016); the 3rd largest Indian pharmaceutical company by revenues; the 6th largest generic pharmaceutical player in Japan and the 4th largest generic pharmaceutical company in South Africa (IMS Health, March 2016).

For the financial year ended 31st March, 2016, Lupin’s Consolidated sales and Net profit stood at Rs. 136,539 million (USD 2.09 billion) and Rs. 22,607 million (USD 345 million) respectively. Please visit http://www.lupin.com for more information. You could also follow us on Twitter – www.twitter.com/lupinlimited

CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.

For further information or queries please contact –

Shamsher Gorawara
Head – Corporate Communications
Ph: +91-98 20 338 555
Email: shamshergorawara@lupin.com


Arvind Bothra
Head – Investor Relations and M&A
Ph: +91-70 45 656 895
Email: arvindbothra@lupin.com 

*Safe Harbor Statement

Vfend® is the registered trademark of Pfizer Ireland Pharmaceuticals